An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

NCT06910137 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Anal Canal

Interventions

DRUG: retifanlimab

Sponsor

Incyte Corporation